title: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.
abstract: The expression of high levels of P-glycoprotein (Pgp) in circulating mononuclear cells allowed us to use an ex vivo assay as a surrogate measure of Pgp antagonism. Efflux of rhodamine from CD56(+) cells was measured before the start of PSC 833 and at varying times thereafter. Patients receiving PSC 833 had decreased rhodamine efflux from their circulating CD56(+) cells. Time course studies showed that following a single oral dose of PSC 833, decreased rhodamine efflux was found in some patients within 15 minutes of treatment. Maximal inhibition was observed at times ranging from 45 minutes to 60 minutes. A dose-response relationship was shown between the concentration of PSC 833 in the blood and the inhibition of rhodamine efflux, with an apparent plateau of the inhibition of rhodamine efflux at approximately 1,000 ng/mL. The Ki, defined as the concentration required for half-maximal inhibition of Pgp-mediated rhodamine efflux, was determined to be in the range of 29 to 181 ng/mL; although results in two patients were distinctly different, with Ki values of 914 and 916 ng/mL. MRK-16 staining was similar among all patients. We conclude that measurement of rhodamine efflux from CD56(+) cells provides a surrogate assay with the potential for monitoring Pgp antagonism in clinical trials.
authors.affiliation: Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: R
authors.initials: R
authors.lastname: Robey
authors.forename: S
authors.initials: S
authors.lastname: Bakke
authors.forename: W
authors.initials: W
authors.lastname: Stein
authors.forename: B
authors.initials: B
authors.lastname: Meadows
authors.forename: T
authors.initials: T
authors.lastname: Litman
authors.forename: S
authors.initials: S
authors.lastname: Patil
authors.forename: T
authors.initials: T
authors.lastname: Smith
authors.forename: T
authors.initials: T
authors.lastname: Fojo
authors.forename: S
authors.initials: S
authors.lastname: Bates
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D015415:Biomarkers; D019002:CD56 Antigen / Q000032:analysis*; D002478:Cells, Cultured; D003524:Cyclosporins / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012235:Rhodamines / Q000378:metabolism*; D013194:Staining and Labeling; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D015415:Biomarkers; D019002:CD56 Antigen; D003524:Cyclosporins; D012235:Rhodamines; D014747:Vinblastine; D017239:Paclitaxel; C070272:valspodar